September is typically not good for the market, says NYSE floor trader Kenny Polcari. Is there pain ahead?» Read More
That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer.
Jim Cramer explains what to watch ahead of the open, including a major breakthrough for Regeneron and troubles for Conn's Inc.
NEW YORK, Aug 29- A year after Goldman Sachs bungled a software upgrade and lost tens of millions of dollars from unintended trades, the 12 U.S. stock options exchanges have crafted new rules for dealing with erroneous transactions, according to draft documents seen by Reuters.
CNBC's Dominic Chu and Art Cashin, of UBS, discuss today¿s trading volume and look ahead to market moving events set to take place next week.
One research firm has detailed how Yale professor Robert Shiller's own economic indicator could actually be signaling a strong period ahead for equities.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss geopolitical uncertainties and their impact on the markets.
Several hotspots across Long Island's playground for the rich have run low on both local and imported vintages of the pink wine.
Bespoke Investment Group released a note of all the analyst ratings on S&P 500 stocks, after the index hit 2,000. CNBC's Dominic Chu has the details.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss S&P 2,000 and QE talk coming out of Europe. The market is trying to find itself, he says.
Duncan Niederauer, NYSE former CEO, looks back at challenges and achievements over his career at the New York Stock Exchange, with CNBC's Bob Pisani and "Closing Bell" panel.
Contrary to what many observers have speculated, Burger King won't be able to justify much of the Tim Hortons deal through tax advantages.
FMHR trader Pete Najarian explains options activity in Citi shares, and Jon Najarian looks at the pop in Cheniere Energy.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss why there are concerns about a lack of conviction in the markets despite record highs.
Jim Cramer explains what to watch ahead of the open, including DSW and GT Advanced Technologies. Cramer also reveals some undervalued stocks that took the S&P to 2,000.
Hang on to your party hats—NYSE floor trader Kenny Polcari says S&P 2,000 wasn't the end game.
Shares of Tim Hortons surged on news that Burger King may buy it. The Canadian company's stock may yet have room to run.
CNBC's Bob Pisani and Art Cashin, of UBS, discuss why the market is going higher, and what traders can expect after Labor Day.
CNBC's Jim Cramer and Carl Quintanilla discuss the action in biotech stocks.
JPMorgan has noted it is keeping its neutral rating on JC Penney, but believes shares are set up for a long trade into the year-end. CNBC's Jim Cramer shares his opinions.
CNBC's Jim Cramer addresses what's really driving stocks, like Walgreen and Gilead Sciences.